The Molecular Medicine Practice provides communication counsel and services to companies and related policy organizations focused on new technologies, products, policies and issues in the emerging field of genomic medicine and health. We believe this arena differs from traditional biopharmaceutical enterprises in that all its key target constituencies have new and different personal and business concerns. It is therefore essential to address – early and simultaneously – all the strategic challenges of corporate positioning, product positioning and marketing, branding, reimbursement, ethics and privacy, legislative affairs, patient and physician education and corporate valuation and financing – to achieve business success.
To address the multi-faceted nature of the issues and opportunities in the field, FKH is collaborating with a network of senior executives, physicians, economists and other practitioners who have decades of experience relating to scientific innovation and commercialization in the biomedical industry, government and academia.
For more information, contact Marcia A. Kean, Chief Executive Officer.
